1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow Safety Issues: new trials by email Literature Review of Safety Issues trials Research Report on Safety Issues
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis Methylprednisolone Injectable Suspension, Belimumab Injection, Immunosuppressive Agents - Lupus Nephritis, Remission | Phase 3 | Unknown | Nanjing University School of Medicine | 15 | 2023-04-01 | 2023-05-18 |
Lupus Nephritis (1)
Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glomerulonephritis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Lupus Erythematosus, Systemic (1) · Male Urogenital Diseases (1) · Nephritis (1) · Skin and Connective Tissue Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Immunosuppressive Agents (1) · belimumab (1)
Nanjing University School of Medicine (1)
China (1)
Zhi-Hong Liu, MD (1)